Literature DB >> 16111446

Drug-drug interactions and tolerance in combining antituberculosis and antiretroviral therapy.

Giovanni Di Perri1, Diego Aguilar Marucco, Alessandra Mondo, Daniel Gonzalez de Requena, Sabrina Audagnotto, Federico Gobbi, Stefano Bonora.   

Abstract

Worldwide, tuberculosis (TB) is one of the most important infectious diseases in subjects with HIV infection. Although effective therapy is available for both conditions, there are major problems in the concurrent treatment of HIV and TB co-infection. In this article the knowledge available on drug-drug interactions between anti-HIV and anti-TB compounds is analysed, particularly with regard to pharmacological interactions secondary to interference with cytochrome P450 enzymes. Within the same setting, facts and possible interpretations of the problems encountered in terms of tolerance and safety of the concurrent treatment of TB and HIV are also reviewed. Current guidelines, as well as additional possible strategies to be adopted in this particular co-morbidity setting are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16111446     DOI: 10.1517/14740338.4.5.821

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  7 in total

Review 1.  Initiating antiretrovirals during tuberculosis treatment: a drug safety review.

Authors:  Tanuja N Gengiah; Andrew L Gray; Kogieleum Naidoo; Quarraisha Abdool Karim
Journal:  Expert Opin Drug Saf       Date:  2011-01-05       Impact factor: 4.250

Review 2.  Evidence-based guideline: Antiepileptic drug selection for people with HIV/AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy.

Authors:  G L Birbeck; J A French; E Perucca; D M Simpson; H Fraimow; J M George; J F Okulicz; D B Clifford; H Hachad; R H Levy
Journal:  Neurology       Date:  2012-01-04       Impact factor: 9.910

3.  Identification of 1-[4-Benzyloxyphenyl)-but-3-enyl]-1H-azoles as New Class of Antitubercular and Antimicrobial Agents.

Authors:  Namrata Anand; K K G Ramakrishna; Munna P Gupt; Vinita Chaturvedi; Shubhra Singh; Kishore K Srivastava; Prapunjika Sharma; Niyati Rai; Ravishankar Ramachandran; A K Dwivedi; Varsha Gupta; Brijesh Kumar; Smriti Pandey; Praveen K Shukla; Shailandra K Pandey; Jawahar Lal; Rama Pati Tripathi
Journal:  ACS Med Chem Lett       Date:  2013-08-26       Impact factor: 4.345

4.  Pharmacokinetic interaction study of ritonavir-boosted saquinavir in combination with rifabutin in healthy subjects.

Authors:  Xiaoping Zhang; Scott Fettner; Elke Zwanziger; Lucy Rowell; Miklos Salgo
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

Review 5.  Co-infection with human immunodeficiency virus and tuberculosis in Asia.

Authors:  Sten H Vermund; Naoki Yamamoto
Journal:  Tuberculosis (Edinb)       Date:  2007-07-16       Impact factor: 3.131

6.  ChemDIS-Mixture: an online tool for analyzing potential interaction effects of chemical mixtures.

Authors:  Chun-Wei Tung; Chia-Chi Wang; Shan-Shan Wang; Pinpin Lin
Journal:  Sci Rep       Date:  2018-07-03       Impact factor: 4.379

7.  Disease extent and anti-tubercular treatment response correlates with Mycobacterium tuberculosis-specific CD4 T-cell phenotype regardless of HIV-1 status.

Authors:  Catherine Riou; Elsa Du Bruyn; Sheena Ruzive; Rene T Goliath; Cecilia S Lindestam Arlehamn; Alessandro Sette; Alan Sher; Daniel L Barber; Robert J Wilkinson
Journal:  Clin Transl Immunology       Date:  2020-09-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.